Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities: 2015-2024

Historic Cash from Financing Activities for Rhythm Pharmaceuticals (RYTM) over the last 9 years, with Dec 2024 value amounting to $191.2 million.

  • Rhythm Pharmaceuticals' Cash from Financing Activities rose 7496.35% to $189.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $259.2 million, marking a year-over-year increase of 66.89%. This contributed to the annual value of $191.2 million for FY2024, which is 157.16% up from last year.
  • Per Rhythm Pharmaceuticals' latest filing, its Cash from Financing Activities stood at $191.2 million for FY2024, which was up 157.16% from $74.4 million recorded in FY2023.
  • Over the past 5 years, Rhythm Pharmaceuticals' Cash from Financing Activities peaked at $213.8 million during FY2022, and registered a low of $2.0 million during FY2020.
  • Moreover, its 3-year median value for Cash from Financing Activities was $191.2 million (2024), whereas its average is $159.8 million.
  • As far as peak fluctuations go, Rhythm Pharmaceuticals' Cash from Financing Activities slumped by 98.77% in 2020, and later skyrocketed by 8,186.76% in 2021.
  • Yearly analysis of 5 years shows Rhythm Pharmaceuticals' Cash from Financing Activities stood at $2.0 million in 2020, then spiked by 8,186.76% to $166.5 million in 2021, then climbed by 28.44% to $213.8 million in 2022, then plummeted by 65.22% to $74.4 million in 2023, then spiked by 157.16% to $191.2 million in 2024.